S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
The only accurate crypto trading system I know … (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Your Money is Not Safe (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
The only accurate crypto trading system I know … (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Your Money is Not Safe (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
The only accurate crypto trading system I know … (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Your Money is Not Safe (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
The only accurate crypto trading system I know … (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Your Money is Not Safe (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial

Compare Stocks

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare
No chart data

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pfenex Inc. stock logo
PFNX
Pfenex
$12.75
$0.00
$5.26
▼
$14.00
$437.29MN/A503,865 shsN/A
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/A0.00∞N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Pfenex Inc. stock logo
PFNX
Pfenex
N/A

Insider Ownership

CompanyInsider Ownership
Pfenex Inc. stock logo
PFNX
Pfenex
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Pfenex Inc. stock logo
PFNX
Pfenex
7134.30 millionN/ANot Optionable

NCYT, PFNX, and TILS Headlines

SourceHeadline
NKY Medical Holdings Ltd Class A 300109NKY Medical Holdings Ltd Class A 300109
morningstar.com - January 31 at 6:39 PM
Last available seats at PFS West Coast Conference next weekLast available seats at PFS West Coast Conference next week
pharmaphorum.com - May 19 at 6:04 PM
Ligand Pharmaceuticals and Playa Hotels Resorts Exceed Q1 ... - Best StocksLigand Pharmaceuticals and Playa Hotels Resorts Exceed Q1 ... - Best Stocks
news.google.com - May 4 at 7:30 PM
150+ Active Companies working to develop 160+ Pipeline ... - Digital Journal150+ Active Companies working to develop 160+ Pipeline ... - Digital Journal
news.google.com - April 13 at 12:19 AM
Heres Why You Should Add Ligand (LGND) Stock to Your Portfolio - NasdaqHere's Why You Should Add Ligand (LGND) Stock to Your Portfolio - Nasdaq
news.google.com - April 6 at 5:35 PM
LENZ Therapeutics Closes $83.5M Series B - San Diego Business JournalLENZ Therapeutics Closes $83.5M Series B - San Diego Business Journal
news.google.com - March 29 at 1:06 PM
Ranibizumab Biosimilars Report 2023: Therapies and Ranibizumab ... - Digital JournalRanibizumab Biosimilars Report 2023: Therapies and Ranibizumab ... - Digital Journal
news.google.com - March 17 at 10:21 AM
Global Inflammatory Bowel Disease (IBD) Therapeutics Market to ... - GlobeNewswireGlobal Inflammatory Bowel Disease (IBD) Therapeutics Market to ... - GlobeNewswire
news.google.com - March 15 at 8:24 PM
San Diegos Lenz Therapeutics snags $83.5M for once-a-day eye ... - The San Diego Union-TribuneSan Diego's Lenz Therapeutics snags $83.5M for once-a-day eye ... - The San Diego Union-Tribune
news.google.com - March 15 at 8:24 PM
Osteoporosis Treatment research scope: In-depth Growth Analysis ... - Digital JournalOsteoporosis Treatment research scope: In-depth Growth Analysis ... - Digital Journal
news.google.com - March 13 at 7:40 AM
Current and Future Analysis of Osteoporosis Treatment Market With New Business Strategies and Forecast by 2030 - openPRCurrent and Future Analysis of Osteoporosis Treatment Market With New Business Strategies and Forecast by 2030 - openPR
news.google.com - March 1 at 11:39 AM
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results - The Bakersfield CalifornianLigand Reports Fourth Quarter and Full Year 2022 Financial Results - The Bakersfield Californian
news.google.com - February 23 at 5:24 PM
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results - Business WireLigand Reports Fourth Quarter and Full Year 2022 Financial Results - Business Wire
news.google.com - February 22 at 5:46 PM
Biosimilar Growth Hormones Global Market Report 2023 - Yahoo FinanceBiosimilar Growth Hormones Global Market Report 2023 - Yahoo Finance
news.google.com - February 8 at 4:13 PM
Biosimilar Therapeutic Peptides Global Market Report 2023 - Yahoo FinanceBiosimilar Therapeutic Peptides Global Market Report 2023 - Yahoo Finance
news.google.com - February 8 at 4:13 PM
Osteoporosis Treatment Market Set to Witness Explosive Growth By ... - Digital JournalOsteoporosis Treatment Market Set to Witness Explosive Growth By ... - Digital Journal
news.google.com - February 7 at 3:49 AM
Injectable Drug Delivery Market Dynamic Demand, Growth ... - PharmiWeb.comInjectable Drug Delivery Market Dynamic Demand, Growth ... - PharmiWeb.com
news.google.com - January 27 at 9:00 PM
Osteoporosis Treatment Market Research Scope: In-Depth Growth ... - Digital JournalOsteoporosis Treatment Market Research Scope: In-Depth Growth ... - Digital Journal
news.google.com - January 27 at 9:34 AM
Injectable Drug Delivery Market 2023 Segmentation and Regional Analysis by 2032 - openPRInjectable Drug Delivery Market 2023 Segmentation and Regional Analysis by 2032 - openPR
news.google.com - January 6 at 1:28 PM
Abzena Names Matthew Stober CEO - Contract PharmaAbzena Names Matthew Stober CEO - Contract Pharma
news.google.com - January 5 at 2:36 PM
Abzena hires Matthew Stober to lead the company through the next ... - Bio-IT WorldAbzena hires Matthew Stober to lead the company through the next ... - Bio-IT World
news.google.com - January 4 at 5:54 PM
Osteoporosis Treatment Market Will Reflect Significant Growth Prospects during 2022 – 2028 | Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED. - Digital JournalOsteoporosis Treatment Market Will Reflect Significant Growth Prospects during 2022 – 2028 | Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED. - Digital Journal
news.google.com - December 7 at 8:29 AM
Ligand Reports Third Quarter 2022 Financial Results - StreetInsider.comLigand Reports Third Quarter 2022 Financial Results - StreetInsider.com
news.google.com - November 8 at 4:47 AM
Krystal Biotech Stock: A Buy For Growth Potential (NASDAQ:KRYS) - Seeking AlphaKrystal Biotech Stock: A Buy For Growth Potential (NASDAQ:KRYS) - Seeking Alpha
news.google.com - November 6 at 2:43 AM

Company Descriptions

Pfenex logo

Pfenex

NYSEAMERICAN:PFNX
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.